Reading CTEV? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track CTEV free→Reading CTEV? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track CTEV free→NYSEHealth CareHealth Information ServicesSnapshot 2026-06-22
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
The thesis is that CTEV's growth potential is strong despite recent challenges. The company has shown strong recent financial performance. However, it remains unprofitable, which raises concerns about earnings quality. CTEV trades at a valuation that is below peer multiples. This suggests it looks cheap, but there is a risk of a value trap. If CTEV misses earnings again, it could face continued pressure. The read is cheap, with value-trap risk.
Daily closes. Earnings/event dots are placed inline.
A consensus fair price across 2 valuation methods, at three horizons. Current price $28.51. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
No-growth: today's peer multiple on trailing earnings. The headline read.
Embeds projected growth. Leans optimistic by design. Upside context.
We take the 12-month fair value above and grade our own number — how the market prices this name versus what we'd justify, and where the two diverge.
At $29 CTEV trades at 0× p/s, below its 2× p/s peer median. Our $62 fair value sits well above the price. We hold it with low confidence: its earnings are too depressed to value on P/E (we anchor on sales instead) and the peer anchor overstates how cheap it looks. Analysts target $28–$61. Note: our $62 fair value sits above the entire analyst range ($28–$61). Not investment advice.
One valuation read at a 12-month horizon, plus how price compares to peers and the company's own history.
The price sits about 55% below a flat-multiple fair value, while analysts forecast about 4% growth — below our forecast. This describes what's priced in, not a forecast of the move.
TTM earnings are negative, so the read leans on sales- and cash-flow-based methods rather than P/E. This is a data condition, not a forward call.
No fragility gates fired. Regime (Mania) does not concentrate fragility.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 1 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated strong grew net income 59% of the time over the next year (vs 52% for the rest of the cohort, n=2344).
Over the trailing year it converted -0.35x of net income into operating cash flow.
Not enough signal yet.
Not enough signal to read sensitivity to the broad stock market, the US dollar, real (inflation-adjusted) rates, long-term interest rates, Fed net liquidity.
14 material management or governance events in the past 24 months, led by executive changes. Historically, Health Care names rated neutral grew net income 58% of the time over the next year (vs 50% for the rest of the cohort, n=842).
The next print and the backdrop around it (sector regime and the AI cycle). Context for the path, not a forecast of returns.
EPS estimate $1.43 → $1.33 (-7.0% / 30d). 0 raised, 0 cut, 1 covering analysts.
0 upgrades, 0 downgrades / 30d. 83% of analysts rate Buy.
1 PT revisions / 30d. Avg target 144.0% above current price.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
What a normal day, a bad day, and the worst of the last year would mean for a $10,000 position.
On a typical day, $10k can swing ±$394.
How much price usually moves either way.
On a bad day, this stock has moved -$915.
A rough but not unusual down day (about the 95th percentile).
In the worst 12 months, $10k could have lost $8,144.
Deepest peak-to-trough drop in the last year.
Past results, not a forecast. Not investment advice.
The most important moves since the prior daily snapshot.
Signal changed from 'None' to 'cautious'.
No, our read on the company is unchanged. There are no new strengths or weaknesses identified. The confidence level has improved from medium to high. The signal changed from none to mixed, indicating some uncertainty.
as of 2026-06-22
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
No named catalysts to watch right now. Check back after the next earnings report.
Recent news graded against this company's own objectives — whether it reinforces or challenges the thesis, and how confirmed it is.
No graded news catalysts for CTEV yet.
Conditional scenarios: if X happens, the view would shift in this direction. These are not predictions.
Recent SEC 8-K filings ranked by likely impact, confidence, and recency.
Results of Operations and Financial Condition. On May 7, 2026, the Company issued a press release announcing its financial results for the first quarter ended March 31, 2026. A copy of the press release is included as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information in this Item 2.02, including 99.1, is furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities and Exchange Act of 1934, as amended (the "Exchan…
Whether the overall read has been drifting up or down lately, and how it's changed since last week.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Long-thesis check; widest uncertainty.
TTM earnings are negative. P/E-based methods drop out and the estimate leans on sales- and cash-flow-based methods. A data condition, not a forward call.
$28.00 – $61.00 (median $34.00) · 4 analysts · as of 2026-06-03
For similar setups historically (n=20,154): about 33% saw a 20%+ drawdown, and roughly 76% of those did not recover within the year. These are historical base rates for the cohort, not a forecast of this stock.
Looks cheaper than most peers in the same business.
Self-history needs ~20 months of data.
Trailing four: 2025-Q1, 2025-Q2, 2025-Q3, 2026-Q1
A side-by-side read on sector standing, valuation, and risk versus peers.
| Stock | Sector standing | Valuation | Risk |
|---|---|---|---|
CTEV Claritev Corp. | Below typical Show detailsSector percentile: 23 of 100 | inexpensive | elevated |
Not investment advice. As of 2026-06-22.
via XLV
Tailwind = sector leading the S&P 500; headwind = trailing. Both can be constructive. Historically, headwind regimes have averaged stronger forward returns than tailwind.
Context label only: describes the market state (e.g. real bear vs narrative panic, healthy uptrend vs late-stage froth). It is not a per-ticker buy/sell signal and does not predict factor performance.
Not investment advice. As of 2026-06-22.
Focus on improving operating income and cash from operations to reduce net losses and negative cash flow trends.
Stated in 6 of last 6 quarters. Operating income improved from a loss of $7.6 million in 2025-Q4 to a positive $6.6 million in 2026-Q1, showing some recovery. However, cash from operations declined from $61.2 million in 2025-Q2 to negative $45.8 million in 2026-Q1, indicating mixed progress. The trajectory shows partial delivery on operating income but volatile cash flow.
“Operating income was $6.6 million, improving from prior quarter loss.”
“Operating income was negative $7.6 million.”
“Operating income was $10.1 million.”
“Operating income was $16.6 million.”
“Operating income was $9.7 million.”
“Operating income was negative $41.4 million.”
Maintain and grow quarterly revenue near the $240 million level to support financial stability and growth.
Stated in 6 of last 6 quarters. Revenue has remained stable around $240 million quarterly, increasing slightly from $233.5 million in 2024-Q2 to $244.7 million in 2026-Q1. This indicates a stable revenue base with limited growth, consistent with management's stated priority.
Results of Operations and Financial Condition. On February 23, 2026, the Company issued a press release announcing its financial results for the fourth quarter and full year ended December 31, 2025. A copy of the press release is included as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information in this Item 2.02, including 99.1, is furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities and Exchange Act of 1934,…
The filing describes an amendment to the company's incentive plan, which is not a management change.
Other Events. On February 23, 2026, the Company announced that its Board of Directors (the “Board”) approved a share repurchase program (the “Share Repurchase Program”) pursuant to which the Company is authorized to purchase up to $75.0 million of its Class A common stock from time to time in open market transactions, subject to general market conditions, compliance with applicable legal requirements, and other considerations. The Share Repurchase Program was approved starting January 1, 2026…
strategic advisor — Dale White: Mr. White will terminate his service as a strategic advisor to the Company.
“Revenue was $244.7 million.”
“Revenue was $246.6 million.”
“Revenue was $246.0 million.”
“Revenue was $241.6 million.”
“Revenue was $231.3 million.”
“Revenue was $232.1 million.”